Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (<scp>TOLERANT</scp> study)—A non‐inferiority, randomized controlled trial
Tolerating up to 100 μm subfoveal subretinal fluid achieves good visual outcomes in our 24-month follow-up period, in patients treated with aflibercept for nAMD, with significantly fewer injections needed.
Authors
- Sebastián Wolf
- Matthias Becker (ORCID: https://orcid.org/0000-0003-4933-7010)
- Sandrine Zweifel (ORCID: https://orcid.org/0000-0001-7431-1774)
- Joel‐Benjamin Lincke (ORCID: https://orcid.org/0000-0002-3257-3757)
- Martin Sebastian Zinkernagel (ORCID: https://orcid.org/0000-0003-3447-2359)
- Odile Stalder (ORCID: https://orcid.org/0000-0002-5563-2975)
- Lieselotte Berger
- Oussama Habra (ORCID: https://orcid.org/0000-0003-2356-3132)
- Damian Jaggi (ORCID: https://orcid.org/0000-0002-3670-6983)
- Stephan Michels (ORCID: https://orcid.org/0000-0002-3146-7805)
Institutions
- University of Bern (CH)
- University of Zurich (CH)
- Heidelberg University (DE)
- University Hospital of Bern (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Acta Ophthalmologica
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1111/aos.17514
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer